Stromal cells – also known as mesenchymal stem cells (MSCs) – are non-hematopoietic, multipotent, self-renewable cells that are capable of trilineage differentiation (mesoderm, ectoderm, and ...

This valuable study presents a novel approach to enhance the therapeutic potential of mesenchymal stromal cells (MSCs) by genetically modifying their glycogen synthesis pathway, resulting in increased ...

Mesenchymal stromal cells (MSCs) are multipotent cell populations obtained from fetal and adult tissues. They share some characteristics with limb bud mesodermal cells such as differentiation ...

Human mesenchymal stromal cells (hMSCs) are widely used in cell therapy because of their ease of harvest, self-renewal, and ability to suppress activation of innate and adaptive immune response.

“Allogeneic mesenchymal stromal cells (MSCs) are a safe treatment option for many disorders of the immune system,” the researchers wrote. “However, clinical trials using MSCs have shown ...

Background: Mesenchymal stromal cells (MSCs) have emerged as a potential alternative therapeutic strategy for the prophylaxis of graft-versus-host disease (GVHD) in patients undergoing hematopoietic ...

NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the ...

Newly published results from a Phase I clinical trial suggest that mesenchymal stromal cells (MSCs, a type of cell derived from bone marrow and other bodily tissue) can be used as a safe and ...

The Food and Drug Administration (FDA) approved the first mesenchymal stromal cell (MSC) therapy, RYONCIL®, indicated for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children ...

Mesoblast’s Ryoncil ® is the first US FDA-approved mesenchymal stromal cell (MSC) therapy. News release. Mesoblast Limited. December 18, 2024.